Sort
82,697 grants matching “vaccine development”
DEVELOPMENT OF ANTHRAX VACCINE FORMULATIONS
$3,818,071John Troyer · Pharmathene, Inc. · N01 · FY2016 · AI
Frontiers Clinical and Translational Science Institute at the University of Kansas
$3,817,944Mario Castro · University Of Kansas Medical Center · UL1 · FY2023 · TR
Frontiers Clinical and Translational Science Institute at the University of Kansas
$3,817,944Mario Castro · University Of Kansas Medical Center · UL1 · FY2024 · TR
B Cell Biology
$3,817,146Susan Pierce · National Institute Of Allergy And Infectious Diseases · ZIA · FY2021 · AI
The University of North Carolina Center for AIDS Research
$3,815,753Ronald I Swanstrom · Univ Of North Carolina Chapel Hill · P30 · FY2020 · AI
Units for HIV/AIDS Clinical Trials Networks
$3,811,633Ian Matthias Sanne · Wits Health Consortium (Pty), Ltd · U01 · FY2009 · AI
Influenza Vaccine Development
$3,806,087Barney Graham · National Institute Of Allergy And Infectious Diseases · ZIA · FY2019 · AI
HIV Vaccine Trials Network Laboratory Center
$3,805,979Margaret Juliana McElrath · Fred Hutchinson Cancer Center · UM1 · FY2022 · AI
Development of Technologies to Facilitate the use and Response of Vaccines
$3,804,245Marc Joseph Gurwith · Paxvax, Inc. · N01 · FY2010 · AI
Advanced Development of Vaccines for Infectious Diseases
$3,802,919Ly Phan · Versatope Therapeutics, Inc. · N01 · FY2020 · AI
Mechanisms of protective immunity induced by live attenuated SIV vaccines
$3,801,627R. Paul Johnson · Harvard Medical School · P01 · FY2008 · AI
Messenger RNA Immunogens for initiation of protective HIV non-neutralizing antibodies
$3,798,808Barton F Haynes · Duke University · U19 · FY2020 · AI
A Phase I/IIa Clinical Trial Testing the Safety and Immunogenicity of a Heroin Vaccine and its Efficacy Against Morphine Challenge.
$3,797,321Gary R. Matyas · Henry M. Jackson Fdn For The Adv Mil/Med · UG3 · FY2019 · DA
Southern California Primary Infection Program
$3,797,136University Of California San Diego · U01 · FY2004 · AI
The UNC/Emory Center for Innovative Technology (iTech) across the prevention and care continuum
$3,796,476Lisa B Hightow-Weidman · Univ Of North Carolina Chapel Hill · U19 · FY2016 · HD
NIAID SPECIMEN REPOSITORY
$3,796,469Deborah Phippard · Precision Bioservices, Inc. · N01 · FY2018 · AI
Development of Antivirals against Filovirus Replication
$3,796,046Ralph S Baric · Univ Of North Carolina Chapel Hill · U19 · FY2022 · AI
UCLA AIDS Prevention and Treatment Clinical Trials Unit
$3,794,297Judith S. Currier · University Of California Los Angeles · UM1 · FY2023 · AI
Pediatric Brain Tumor Consortium A multi-institutional consortium devoted to novel phase I and II clinical evaluations of experimental treatment approaches for pediatric CNS tumors
$3,793,439Arzu Onar-Thomas · St. Jude Children'S Research Hospital · UM1 · FY2025 · CA
New Jersey Alliance for Clinical and Translational Science: NJ ACTS
$3,792,941Reynold Alexander Panettieri · Rutgers Biomedical/Health Sciences-Rbhs · UL1 · FY2020 · TR
Phase 1a/1b Clinical Trials of Multivalent Opioid Vaccine Components
$3,788,472Sandra D. Comer · New York State Psychiatric Institute Dba Research Foundation For Mental Hygiene, Inc · UG3 · FY2019 · DA
ARRA ^ H1N1 Influenza Comparative Pathogenesis
$3,787,927Jeffery Taubenberger · National Institute Of Allergy And Infectious Diseases · ZIA · FY2010 · AI
Rapid Optimization of COVID-19 Testing for People Affected by Diabetes
$3,786,234Kabayam M Venkat Narayan · Emory University · P30 · FY2020 · DK
Development of Therapeutic Candidates for Biodefense, Infections and Emerging Infectious Diseases
$3,781,845Emily Voigt · Access To Advanced Health Institute · N01 · FY2024 · AI
IGF::OT::IGF NIAID Specimen Repository
$3,781,713Michael Waddington · Precision Bioservices, Inc. · N01 · FY2013 · AI